Iterum Therapeutics Statistics Share Statistics Iterum Therapeutics has 44.66M
shares outstanding. The number of shares has increased by 62.29%
in one year.
Shares Outstanding 44.66M Shares Change (YoY) 62.29% Shares Change (QoQ) 11.64% Owned by Institutions (%) 0.22% Shares Floating 44.25M Failed to Deliver (FTD) Shares 113 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 1.37M, so 3.07% of the outstanding
shares have been sold short.
Short Interest 1.37M Short % of Shares Out 3.07% Short % of Float 3.1% Short Ratio (days to cover) 2.16
Valuation Ratios The PE ratio is -1.41 and the forward
PE ratio is -2.48.
Iterum Therapeutics's PEG ratio is
0.02.
PE Ratio -1.41 Forward PE -2.48 PS Ratio 0 Forward PS 1.7 PB Ratio -8.54 P/FCF Ratio -1.3 PEG Ratio 0.02
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Iterum Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.41,
with a Debt / Equity ratio of -11.16.
Current Ratio 1.41 Quick Ratio 1.41 Debt / Equity -11.16 Debt / EBITDA -2.44 Debt / FCF -1.7 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.75M Employee Count 9 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 240K Effective Tax Rate -0.98%
Stock Price Statistics The stock price has increased by -33% in the
last 52 weeks. The beta is 3.23, so Iterum Therapeutics's
price volatility has been higher than the market average.
Beta 3.23 52-Week Price Change -33% 50-Day Moving Average 0.72 200-Day Moving Average 1.13 Relative Strength Index (RSI) 43.68 Average Volume (20 Days) 840,207
Income Statement
Revenue n/a Gross Profit -254K Operating Income -18.7M Net Income -24.77M EBITDA -18.7M EBIT -18.7M Earnings Per Share (EPS) -1.26
Full Income Statement Balance Sheet The company has 24.13M in cash and 45.53M in
debt, giving a net cash position of -21.41M.
Cash & Cash Equivalents 24.13M Total Debt 45.53M Net Cash -21.41M Retained Earnings -486.07M Total Assets 34.01M Working Capital 9.36M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -26.77M
and capital expenditures -2K, giving a free cash flow of -26.77M.
Operating Cash Flow -26.77M Capital Expenditures -2K Free Cash Flow -26.77M FCF Per Share -1.36
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ITRM does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ITRM is $9,
which is 1243.3% higher than the current price. The consensus rating is "Buy".
Price Target $9 Price Target Difference 1243.3% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 18, 2022. It was a
backward
split with a ratio of 1:15.
Last Split Date Aug 18, 2022 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -21.69 Piotroski F-Score 3
